ERBB2 and breast cancer: Patients (n = 64) with locally advanced HER2+ BC received a 12-week course of a dual HER2-targeted blockade with trastuzumab and lapatinib; patients with HR+ BC also received letrozole (plus LHRHa if premenopausal).